The List of Reviewers lists all present, whether permanent or temporary, to provide the full scope of expertise present on that date. Lists are posted 30 days before the meeting and are tentative, pending any last minute changes.

Review Dates

Topics


  • Tumor progression, metastasis and angiogenesis
  • Roles of epithelial-mesenchymal transition (EMT), stress and hypoxia in metastasis, angiogenesis and therapy resistance
  • Tumor cell adhesion, invasion/migration, dormancy and tumor dissemination
  • Tumor microenvironment and host-tumor interactions
  • Translational/clinical studies, including prevention (diet, exercise, chemoprevention), diagnosis (cancer biomarkers), imaging and therapeutic strategies
  • Development and characterization of cancer therapeutics (drug discovery, drug delivery, exosomes, chemotherapy, radiation therapy, miRNA therapeutics, drug resistance, mechanism of action of cancer drugs)
  • Role of chronic inflammation in cancer development and progression

Shared Interests and Overlaps

Fellowship panels are broad and cover inter-related areas. Assignments are made based on the primary emphasis of the proposed research and topics in several fellowship panels overlap as described below. Final assignments are made by the staff at the Center for Scientific Review to ensure that each application has the appropriate expertise to review it.

There are shared interests with the Oncological Sciences A (F09A) fellowship panel in tumor metastasis and progression and tumor cell biology. Applications that focus on tumor cell signaling and metabolism as it relates to therapeutic mechanisms or tumor microenvironment may be assigned to F09B. Applications that focus on tumor cell signaling and basic mechanisms of tumor cell biology may be assigned to F09A.

There are shared interests with the Oncological Sciences C (F09C) fellowship panel in mechanisms of cancer therapeutics and tumor microenvironment. Applications that focus on non-immunological therapies and interactions between tumor cells and stromal cells may be assigned to F09B. Applications that focus on immunotherapeutic strategies and immune cells in the tumor microenvironment may be assigned to F09C.

There are shared interests with the Synthetic and Biological Chemistry A (F04A) fellowship panel in drug development. Applications that focus on functional studies of small molecule inhibitors as cancer therapeutics may be assigned to F09B. Applications that focus on design, synthesis and medicinal chemistry of small molecule inhibitors may be assigned to F04A.

There are shared interests with the Macromolecular Structure and Function B (F04B) fellowship panel in signal transduction and macromolecular interactions. Applications that focus on signal transduction and macromolecular interactions in the context of tumor metastasis, microenvironment or cancer therapeutics may be assigned to F09B. Applications that focus on structural and functional analysis using biophysical methods and computational approaches may be assigned to F04B.

There are shared interests with the Cell Biology, Development Biology and Bioengineering (F05) fellowship panel in bioengineering. Applications that use biomaterials and engineered tissues to answer biological questions in the oncology field may be assigned to F09B. Applications that focus on development of new biomaterials, engineered tissues or drug delivery systems may be assigned to F05.

There are shared interests with the Musculoskeletal and Oral Sciences, Imaging, Surgery, and Informatics (F10B) fellowship panel in diagnostic devices and therapeutics. Applications that focus on cancer treatment (drug discovery, radiation and development of therapeutic strategies) may be assigned to F09B. Applications that focus on tissue engineering, development of diagnostic devices/imaging probes, evaluation of therapeutic devices and systems may be assigned to F10B.

There are shared interests with the Risk, Health and Healthcare (F16) fellowship panel in cancer risk factors. Applications that focus on cancer biomarkers or molecular mechanisms associated with increased cancer risk may be assigned to F09B. Applications that focus on prevalence, prevention and behavioral outcomes of cancer may be assigned to F16.